Charles River Laboratories International, Inc. (CRL) - NYSE
  • Jun. 18, 2013, 9:54 AM

    Goldman downgrades Charles River Labs (CRL -1.7%) to Sell from Neutral and lowers its price target to $38 from $44. Analyst Robert Jones cites (among other factors) "recent … channel checks [which] indicate still subdued early-stage spend and excess capacity as pharma prioritizes late-stage pipelines."

    | Jun. 18, 2013, 9:54 AM
  • May 31, 2013, 3:26 PM
    Charles River Labs (CRL -1.6%) slips on a Raymond James downgrade to Underperform from Market Perform. When asked about the move on CNBC earlier, Cramer said he doesn't agree. In the same segment, the Mad Money host called Guess' (GES +9%) Q1 "horrendous, but not horrendous enough" to keep the shares from rallying. (See also: GES earnings rundown)
    | May 31, 2013, 3:26 PM | 1 Comment
  • Dec. 13, 2012, 1:25 PM

    Charles River Labs (CRL +3.2%) moves higher on a couple of upgrades earlier today. JPMorgan raises its rating on the shares to Overweight, saying the risk-reward is looking good going into 2013. The firm notes that longer term questions still remain, but given the improving fundamentals, ongoing cost discipline and a 10% free cash flow yield, the stock looks attractive at current levels. Separately, Wells Fargo also upped the shares to Outperform on valuation, saying that that guidance looks conservative with the midpoint only 5% below consensus.

    | Dec. 13, 2012, 1:25 PM
  • Dec. 12, 2012, 12:45 PM
    Midday top 10 gainers: YMI +77%. DSTI +73%. TELK +25%. LDK +21%. JKS +23%. JASO +21%. TSL +20%. YGE +19%. CBMX +14%. SOL +17%.
    Midday top 10 Losers: RSOL -14%. CENT -13%. ACUR -11%. TAS -11%. CATO -10%. CRWS -9%. AVD -9%. CRL -8%. AXK -8%. LTBR -8%.
    | Dec. 12, 2012, 12:45 PM
  • Dec. 12, 2012, 9:29 AM

    Charles River Labs (CRL) -5.1% premarket after providing 2013 earnings guidance below expectations, at $2.80-$2.90 per share vs. $3.01 consensus estimate. The drug research services provider also expects 2012 EPS to come in between the low end and the midpoint of its previously estimated range of $2.68-$2.73.

    | Dec. 12, 2012, 9:29 AM
  • Feb. 13, 2012, 4:52 PM
    Charles River Laboratories (CRL): Q4 EPS of $0.69 beats by $0.14. Revenue of $291M (+3.3% Y/Y) beats by $9M. Shares +2.6% AH. (PR)
    | Feb. 13, 2012, 4:52 PM
  • Jan. 10, 2012, 11:25 AM
    Speculation that Charles River Laboratories (CRL) is in play intensifies as management stays mum, shares are now up 22.8% without breaking stride.
    | Jan. 10, 2012, 11:25 AM
  • Jan. 10, 2012, 8:23 AM

    Charles River Labs (CRL) is pursuing a sale of the company that could fetch as much as $40/share, and it's "just a matter of time" before a deal is completed, the Deal Reporter says. R.W. Baird expects shares to trade higher on the speculation unless management denies the story. CRL +2.1% premarket.

    | Jan. 10, 2012, 8:23 AM
  • Aug. 5, 2011, 3:55 PM
    Shares of Charles River Labs (CRL -3.8%) continue to drift lower after hedge fund Jana Partners disclosed late yesterday that had it sold 1.8M shares, reducing it's stake to around 4.8%.
    | Aug. 5, 2011, 3:55 PM
Company Description
Charles River Laboratories International, Inc. is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe to accelerate their research and drug... More
Sector: Healthcare
Industry: Biotechnology
Country: United States